How to calculate Waist-to-Height Ratio WHtR (EN): WHtR is the simple robust anthropometric indicator of cardio-metabolic risk endorsed by the famous slogan "Keep your waist to less than half your height" (Margaret Ashwell, MRC UK, 1996-2014). The calculator implements the classical formula WHtR = waist_circumference / height with central threshold 0.50 and progressive Ashwell-Browning 2014 risk classes. Reference frameworks: NIH National Institutes of Health Bethesda, NHLBI National Heart Lung and Blood Institute, CDC Atlanta, FDA, USPSTF, NHANES, AHA American Heart Association Dallas, ACC American College of Cardiology Washington, AACE American Association of Clinical Endocrinology Jacksonville, TOS The Obesity Society Bethesda, ASMBS bariatric surgery, ADA American Diabetes Association Arlington, Endocrine Society Washington, NCEP National Cholesterol Education Program ATP-III, IDF International Diabetes Federation Brussels; UK NHS National Health Service, NICE National Institute for Health and Care Excellence, BHF British Heart Foundation London, Diabetes UK;

European Society of Cardiology ESC Sophia Antipolis, EASD European Association Study of Diabetes Vienna, EASO European Association Study Obesity, WHO World Health Organization Geneva. Clinical centers: Mayo Clinic Rochester, Cleveland Clinic Heart and Vascular Institute, Johns Hopkins Bayview, Mass General Brigham Boston, NIH Clinical Center Bethesda, Cedars-Sinai LA, Joslin Diabetes Center Boston, Pennington Biomedical Research Center Baton Rouge, Vanderbilt Heart and Vascular; UCLA Cardiovascular Center; Brigham and Women's; Texas Heart Institute Houston; UK Imperial College Healthcare London, Barts Health NHS, Royal Brompton. Anti-obesity pharma: Novo Nordisk Ozempic Wegovy semaglutide, Eli Lilly Indianapolis Mounjaro Zepbound tirzepatide, Boehringer Ingelheim Jardiance empagliflozin SGLT2, AstraZeneca Wilmington Delaware Farxiga dapagliflozin, Pfizer New York, Currax Contrave, Vivus Qsymia, Rhythm Pharmaceuticals setmelanotide.

The universal 0.50 threshold is endorsed by NICE NG7 2022, WHO, AHA, AACE, and most national obesity guidelines.

Ashwell formula and Ashwell-Browning 2014 categories

WHtR = waist_circumference_cm / height_cm; maximum_waist_recommended = height * 0.50; excess_cm = waist - max_waist. The universal 0.50 threshold applies to all adults regardless of sex, age, or ethnicity (huge operational advantage over the sex-age-ethnicity-dependent BMI). Ashwell-Browning 2014 categories for adults ≥15 yrs: WHtR <0.40 very lean (nutritional risk), 0.40-0.49 healthy (optimal range, lowest cardio-metabolic risk), 0.50-0.53 overweight/mild risk, 0.54-0.57 increased risk, 0.58-0.62 high risk, ≥0.63 very high risk. For children and adolescents <15 yrs use simplified WHtR <0.46 underweight, 0.46-0.49 healthy, 0.50-0.53 overweight, ≥0.54 obesity (Ashwell pediatric thresholds). Comparison with BMI: WHtR is better predictor of cardio-metabolic risk than BMI in meta-analyses (Browning Hsieh Ashwell 2010, 31 studies, 300,000 subjects, AUC 0.704 vs 0.671). WHtR captures visceral adiposity (intra-abdominal fat) which BMI does not. Proper measurement: waist at navel or midpoint between iliac crest and lowest rib, relaxed, end-expiration, abdomen not contracted; height standing barefoot, heels together, horizontal gaze.

History WHtR from Hsieh 1995 to NICE 2022

WHtR was proposed in pioneering Japanese studies: Hsieh SD, Yoshinaga H. Sangyo Ika University Kitakyushu 1995 Waist/height ratio as a simple and useful predictor of coronary heart disease risk factors in women. Internal Medicine 34:1147-52 1995 and Hsieh-Yoshinaga 2003 in Japanese cohort of 6,000 subjects demonstrated predictive superiority of WHtR over BMI and WHR Waist-to-Hip Ratio. Margaret Ashwell Medical Research Council MRC UK and later independent consultant with British Nutrition Foundation London popularized WHtR and the slogan "Keep your waist to less than half your height" from 1996 onward in numerous papers (BMJ Open, Obesity Reviews, Nutrition Today). The Browning Hsieh Ashwell 2010 meta-analysis Obesity Reviews 11:165-178 on 31 studies and 300,000 subjects confirmed WHtR predictive superiority (AUC 0.704) over BMI (0.671) and absolute WC waist circumference (0.693) for coronary heart disease, stroke, type 2 diabetes, hypertension, metabolic syndrome. NICE National Institute for Health and Care Excellence UK adopted WHtR in NG7 Obesity Identification, Assessment and Management 2022 recommending threshold 0.50 as complement to BMI, particularly for Asians (lower BMI cutoffs 23/27.5). WHO World Health Organization and FAO/WHO Expert Consultation 2008 recommend WHtR.

In the US AHA AACE TOS guidelines reference WHtR alongside BMI and waist circumference NCEP ATP-III/IDF for metabolic syndrome.

Ashwell-Browning 2014 WHtR categories table

5 numerical WHtR examples

Example 1 male 175 cm waist 85 cm 35 yrs: WHtR = 85/175 = 0.486 -> healthy; max waist 87.5 cm; margin 2.5 cm. Healthy adult optimal range profile.

Example 2 male 180 cm waist 102 cm 50 yrs: WHtR = 102/180 = 0.567 -> increased risk; max waist 90 cm; excess 12 cm. AHA-AACE indication: full metabolic workup glucose HbA1c lipid panel BP ECG abdominal ultrasound (NAFLD MASLD).

Example 3 female 165 cm waist 78 cm 30 yrs: WHtR = 78/165 = 0.473 -> healthy; max waist 82.5 cm; margin 4.5 cm.

Example 4 female 160 cm waist 95 cm 60 yrs: WHtR = 95/160 = 0.594 -> high risk; max waist 80 cm; excess 15 cm. Mediterranean diet -500 kcal/day + 150 min/wk aerobic per AHA-ACSM-ACC; potential GLP-1 semaglutide Wegovy or tirzepatide Zepbound.

Example 5 boy age 12 waist 75 cm height 150 cm: WHtR = 75/150 = 0.500 -> pediatric overweight (Ashwell pediatric cut-off 0.50); pediatric evaluation, Mediterranean diet, 60 min/day physical activity per WHO/AAP guidelines; potential evaluation at children's hospital programs Boston Children's, Cincinnati Children's, Texas Children's.

WHtR model limitations

WHtR does not account for lean mass and may overestimate risk in athletes (oblique-rectus abdominal hypertrophy). In sarcopenic elderly, WHtR may not reflect composition (muscle loss with relative preservation of abdominal fat); supplement with BIA, DEXA, abdominal MRI/CT. WHtR does not finely distinguish visceral from subcutaneous fat (need MRI, CT, ultrasound with VAT/SAT score). For Asians some studies suggest more prudent <0.45 threshold (Lin 2010, Lee 2013 Korean Japanese Chinese cohorts). Not applicable in pregnancy. For children <5 years use age-sex percentiles WHO 0-5. Measurement: +-1 cm waist error produces +-0.005 WHtR (at class boundaries); follow standard navel-level relaxed end-expiration. WHtR does not replace absolute waist circumference NCEP ATP-III/IDF (men >102 cm, women >88 cm) for metabolic syndrome diagnosis. Recommended combination per AHA-AACE: BMI + WHtR + absolute waist circumference + body composition + metabolic profile (glucose, lipids, BP, transaminases, FIB-4 NAFLD).

Common WHtR errors

Common pitfalls: measuring waist too tight (under belt) underestimating WHtR; contracting abdomen; measuring just after large meal (morning fasting preferred); measuring during inspiration instead of relaxed end-expiration; rounding to integer cm losing precision (requires 0.5 cm); applying 0.50 threshold to children <15 with different pediatric cut-offs (0.46-0.54); applying WHtR in pregnancy; confusing WHtR with WHR (Waist-Hip Ratio men <0.90 women <0.85 WHO) and absolute WC NCEP ATP-III/IDF; using WHtR alone without BMI: AHA AACE NICE recommend combination. Ignoring sex difference in 0.40-0.49 range: same threshold but female sex typically has narrower waist for same height due to pelvis-hip physiology. Confusing VAT visceral adipose tissue with SAT subcutaneous adipose tissue: VAT is pathologically more dangerous but requires MRI or CT.

WHtR applications USA UK NHS

1. Cardiometabolic guidelines: AHA American Heart Association Dallas, ACC American College Cardiology, AACE Endocrinology Jacksonville, NCEP ATP-III, IDF International Diabetes Federation Brussels, ADA American Diabetes Arlington; UK NICE NG7 2022, BHF British Heart Foundation, Diabetes UK; ESC European Society Cardiology Sophia Antipolis.
2. Anti-obesity pharma: Novo Nordisk (Ozempic Wegovy semaglutide), Eli Lilly Indianapolis (Mounjaro Zepbound tirzepatide), Boehringer Ingelheim (Jardiance empagliflozin SGLT2), AstraZeneca (Farxiga dapagliflozin), Pfizer (danuglipron), Currax (Contrave), Vivus (Qsymia), Rhythm (setmelanotide).
3. Clinical centers: Mayo Clinic Rochester, Cleveland Clinic Heart Vascular, Johns Hopkins Bayview Center for Obesity, Mass General Boston Brigham Women's, NIH Clinical Center, Cedars-Sinai LA, Pennington Biomedical Baton Rouge, Joslin Diabetes Boston, UCLA Cardiovascular, Texas Heart Institute Houston.
4. National surveillance: NHANES National Health and Nutrition Examination Survey CDC Atlanta NCHS, BRFSS, YRBSS, NHIS; UK Health Survey for England HSE; ELSA English Longitudinal Study of Ageing; Whitehall II civil servants.
5. Pediatrics: Boston Children's Hospital, Cincinnati Children's, Texas Children's Houston, Children's Hospital of Philadelphia CHOP, Seattle Children's, Children's National DC; AAP American Academy of Pediatrics 2023 obesity guidelines; WHO 0-5 growth charts; CDC 2-20 yr percentiles.

Updated July 2026